Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation
Conditions
Brief summary
Palliative radiation therapy represents 40% of the on-going radiation at the Jewish General Hospital. In a traditional palliative radiation treatment to bulky or radioresistant tumors, radiotherapy schema varies from 24 to 30 Gys given in 3 to 10 fractions, depending on the tumor size, tumor location and tumor pathology. However, for many patients this treatment involves considerable toxicity, travel and time spent at the hospital. Spatially fractionated radiation (SFR) is an alternative technique that consists in delivering one single treatment, given through a grid containing holes. The present study is proposing to validate SFR as a safe and effective mean to palliate patients with symptomatic bulky tumors (more than 8 cm) or with tumors known to be resistant to radiation.
Interventions
A single dose of 15-20Gys of spatially fractionated radiation therapy
Sponsors
Sir Mortimer B. Davis - Jewish General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with histologically or cytologically confirmed malignancy. All malignant histologies/cytologies are eligible. * Patient with bulky tumor (larger than 8cm), or with a tumor known to be resistant to radiation (eg. Melanoma, hypernephroma, sarcoma), or with a tumor previously irradiated with a palliative intent requiring more than 1 fraction of radiation * Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis * WHO performance status of 0-2 * Aged 18 years or older * Ability to sign and understand an informed consent form
Exclusion criteria
* Potentially curable patient * Previous palliative radiation with hypofractionation * Tumor located near the spinal cord or in the brain * Pregnant or nursing woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom relief, as measured using the CTCAE grading system (v4.0) and pain questionnaire | 3 months post treatment |
Secondary
| Measure | Time frame |
|---|---|
| Acute toxicity of treatment, as measured using the CTCAE grading system (v4.0) | 1 week |
| Long-term toxicity of treatment, as measured using the CTCAE grading system (v4.0) | 3, 6, 9, 12 months |
| Cost-effectiveness, as measured by evaluating the cost of the procedure per patient and the efficacy of treatment with regards to symptom relief and tumor response | 3 months |
| Tumor response, measured on CT-scan | 8 weeks |
Countries
Canada
Contacts
Primary ContactLuciana Poggi, PhD
Outcome results
None listed